SCHEMBL5162245

SCHEMBL5162245

CCNc1nc(OCCCc2ccccc2)nc2c1nc(Br)n2-c1ccc(OC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.45
CYP3A4 P08684 7/20 0.45
ALDH1A1 P00352 7/20 0.45
TSHR P16473 6/20 0.45
CYP2C9 P11712 5/20 0.45
CYP2C19 P33261 5/20 0.45
CYP2D6 P10635 4/20 0.45
HSD17B10 Q99714 4/20 0.45
CASP1 P29466 3/20 0.45
CASP7 P55210 3/20 0.45
MAPK1 P28482 3/20 0.45
TMIGD3 P0DMS9 3/20 0.43
ADORA2A P29274 3/20 0.43
ADORA2B P29275 3/20 0.43
ADORA1 P30542 3/20 0.43
USP2 O75604 7/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HIF1A Q16665 2/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161171 0.95 CYP1A2 (0.46) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5163187 0.92 TMIGD3 (0.45) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5158701 0.87 ADORA2B (0.42) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5162148 0.85 ADORA2A (0.48) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5161088 0.84 ALDH1A1 (0.42) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5158815 0.84 ADORA1 (0.48) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5161918 0.83 ALDH1A1 (0.49) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5159207 0.82 ALDH1A1 (0.44) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5359337 0.79 ADORA2A (0.46) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9
SCHEMBL5162993 0.75 TMIGD3 (0.54) CYP1A2CYP3A4ALDH1A1TSHRCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
EP-1456209-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2004-09-15 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed
WO-2003051882-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 CYP1A2 1423/4885CYP3A4 3669/4885ALDH1A1 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.